BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34588423)

  • 1. Extramedullary disease in multiple myeloma.
    Bansal R; Rakshit S; Kumar S
    Blood Cancer J; 2021 Sep; 11(9):161. PubMed ID: 34588423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Abnormalities in Extramedullary Multiple Myeloma.
    McAvera R; Quinn J; Murphy P; Glavey S
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research Progress on Multiple Myeloma with Extramedullary Disease].
    Wang L; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):945-8. PubMed ID: 27342539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extramedullary multiple myeloma.
    Weinstock M; Ghobrial IM
    Leuk Lymphoma; 2013 Jun; 54(6):1135-41. PubMed ID: 23210572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extramedullary Disease in Multiple Myeloma.
    Jagosky MH; Usmani SZ
    Curr Hematol Malig Rep; 2020 Apr; 15(2):62-71. PubMed ID: 32198576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
    Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
    PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
    Varga C; Xie W; Laubach J; Ghobrial IM; O'Donnell EK; Weinstock M; Paba-Prada C; Warren D; Maglio ME; Schlossman R; Munshi NC; Raje N; Weller E; Anderson KC; Mitsiades CS; Richardson PG
    Br J Haematol; 2015 Jun; 169(6):843-50. PubMed ID: 26032514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
    Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
    Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma.
    Liu Y; Jelloul F; Zhang Y; Bhavsar T; Ho C; Rao M; Lewis NE; Cimera R; Baik J; Sigler A; Sen F; Yabe M; Roshal M; Landgren O; Dogan A; Xiao W
    Am J Surg Pathol; 2020 Jun; 44(6):838-848. PubMed ID: 32118627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Gagelmann N; Eikema DJ; Koster L; Caillot D; Pioltelli P; Lleonart JB; Reményi P; Blaise D; Schaap N; Trneny M; Passweg J; Porras RP; Cahn JY; Musso M; Poiré X; Fenk R; Itälä-Remes M; Pavone V; Fouillard L; Maertens J; Bron D; Pouli A; Schroyens W; Schönland S; Garderet L; Yakoub-Agha I; Kröger N
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2134-2142. PubMed ID: 31288095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphologic heterogeneity and plasmablastic transformation in advanced plasmacytic/plasmablastic myeloma: a study of 35 serial bone marrow biopsies in 9 patients.
    Paule B; Quillard J; Bennet P; Mariette X; Bisson M
    Nouv Rev Fr Hematol (1978); 1989; 31(3):203-8. PubMed ID: 2616267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetics in multiple myeloma patients progressing into extramedullary disease.
    Besse L; Sedlarikova L; Greslikova H; Kupska R; Almasi M; Penka M; Jelinek T; Pour L; Adam Z; Kuglik P; Krejci M; Hajek R; Sevcikova S
    Eur J Haematol; 2016 Jul; 97(1):93-100. PubMed ID: 26432667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extramedullary disease in multiple myeloma: a systematic literature review.
    Bladé J; Beksac M; Caers J; Jurczyszyn A; von Lilienfeld-Toal M; Moreau P; Rasche L; Rosiñol L; Usmani SZ; Zamagni E; Richardson P
    Blood Cancer J; 2022 Mar; 12(3):45. PubMed ID: 35314675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model.
    Lee BH; Park Y; Kim JH; Kang KW; Lee SJ; Kim SJ; Kim BS
    Sci Rep; 2020 Jul; 10(1):12641. PubMed ID: 32724129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
    Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
    Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
    Weinstock M; Aljawai Y; Morgan EA; Laubach J; Gannon M; Roccaro AM; Varga C; Mitsiades CS; Paba-Prada C; Schlossman R; Munshi N; Anderson KC; Richardson PP; Weller E; Ghobrial IM
    Br J Haematol; 2015 Jun; 169(6):851-8. PubMed ID: 25833301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
    Klein B; Seckinger A; Moehler T; Hose D
    Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements.
    Bergsagel PL; Masellis Smith A; Belch AR; Pilarski LM
    Curr Top Microbiol Immunol; 1995; 194():17-24. PubMed ID: 7534667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.